This study aims to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients.
Delirium is an acute, short-term brain dysfunction characterized by fluctuating consciousness, cognitive decline, inattention, and sleep-wake cycle disruption. Postoperative delirium (POD), occurring predominantly within the first postoperative week (especially days 3-5 in elderly patients), affects 11-45% of older adults after major surgery. POD prolongs hospitalization, increases morbidity and mortality 5,65,6, yet its pathophysiology remains unclear, and evidence-based pharmacological prevention is lacking. Thus, effective POD prevention strategies are urgently needed. Preoperative anxiety, a modifiable risk factor for POD, affects 11-80% of surgical patients. It contributes to sleep disturbances (e.g., insomnia, early awakening), which may exacerbate POD via neuroendocrine and immune dysregulation. However, benzodiazepines (e.g., lorazepam, diazepam, midazolam), though effective anxiolytics, increase delirium risk and are contraindicated preoperatively per current guidelines. Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist, induces physiological non-REM sleep without respiratory depression or hemodynamic instability. Its nasal formulation offers high bioavailability (82%), ease of administration, and is approved in China for preoperative sedation/anxiety. While intravenous (IV) DEX reduces POD in predominant ICU settings, its use in general wards remains unexplored. Preclinical studies suggest DEX enhances glymphatic clearance and exerts anti-inflammatory effects, potentially mitigating the development of POD. This study thus hypothesize that a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patient population. We set to demonstrate that to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in older patients undergoing major abdominal surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
400
Intranasal dexmedetomidine (100 µg total: 4 sprays, 25 µg/spray; Hengrui Medicine, China) self-administered preoperatively (\~9 PM) and optionally on the night of surgery (patient decides dose: 0, 2 sprays, or 4 sprays).
Intranasal water for injection (4 sprays, identical volume as nasal dexmedetomidine; Hengrui Medicine, China) self-administered preoperatively (\~9 PM) and optionally on the night of surgery (patient decides dose: 0, 2 sprays, or 4 sprays).
Incidence of postoperative delirium
Confusion Assessment Method
Time frame: Up to postoperative day (POD) 7 or discharge (whichever first).
Delirium severity
Confusion Assessment Method Score
Time frame: Up to postoperative day (POD) 7 or discharge (whichever first)
Physical activity
Fitbit Flex2 tracker
Time frame: Up to postoperative day (POD) 3
Sleep quality
Fitbit Flex2 tracker and Athens Insomnia Scale
Time frame: Up to postoperative day (POD) 3
Anxiety
Hamilton Anxiety Scale
Time frame: Up to postoperative day (POD) 3
Pain intensity
Numerical Rating Scale
Time frame: Up to postoperative day (POD) 3
Opioid consumption
Intravenous morphine equivalents
Time frame: Up to postoperative day (POD) 3
Health related quality of life
Health related quality of life assessed with the SF-36 health survey
Time frame: On postoperative day (POD) 3 and 30
Quality of Recovery
The Quality of Recovery-15 questionnaire
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to postoperative day (POD) 3
Postoperative Nausea and Vomiting
Postoperative Nausea and Vomiting Scale
Time frame: Up to postoperative day (POD) 3
Post-anesthesia Care Unit (PACU) length of stay
Post-anesthesia Care Unit (PACU) length of stay
Time frame: Up to postoperative day (POD) 1